NSABP B-23

  • NSABP B-23:
    • Was developed in an attempt to determine whether:
      • Tamoxifen was effective:
        • In patients with ER-negative tumors:
          • By randomizing them to:
            • Four cycles of adjuvant doxorubicin and cyclophosphamide (AC) or
            • Six cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF):
              • With or without tamoxifen
    • The results of B-23 demonstrated:
      • No significant improvement in:
        • Disease-free survival (DFS) or OS:
          • With tamoxifen added to chemotherapy in patients with ER-negative tumors:
            • DFS:
              • CMF – 83%
              • CMF plus tamoxifen – 83%
              • AC – 83%
              • AC plus tamoxifen – 82%
            • OS:
              • CMF – 89%
              • CMF plus tamoxifen – 89%
              • AC – 90%
              • AC plus tamoxifen – 91%
    • Additionally:
      • NSABP B-23 confirmed the results of NSABP B-15:
        • That four cycles of AC are equivalent to 6 cycles of CMF:
          • In terms of DFS and OS

#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #Teacher

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s